Topalian, S.L., Drake, C.G. & Pardoll, D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate antitumor immunity. Curr. Opin. Immunol. 24, 207–212 (2012).
Topalian, S.L. et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562 (2014).
Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).
Motzer, R.J. et al. Nivolumab versus everolimus in advanced renal cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
Rizvi, N.A. et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16, 257–265 (2015).
Ansell, S.M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311–319 (2015).
Center for Drug Evaluation Research. Approved Drugs—Hematology/Oncology (Cancer) Approvals & Safety Notifications (US Food and Drug Administration, 2016).
Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134–144 (2013).
Nishino, M., Ramaiya, N.H., Hatabu, H. & Hodi, F.S. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat. Rev. Clin. Oncol. 14, 655–668 (2017).
Wistuba-Hamprecht, K. et al. Establishing high-dimensional immune signatures from peripheral blood via mass cytometry in a discovery cohort of stage IV melanoma patients. J. Immunol. 198, 927–936 (2017).
Pérez-Callejo, D., Romero, A., Provencio, M. & Torrente, M. Liquid-biopsy-based biomarkers in non-small-cell lung cancer for diagnosis and treatment monitoring. Transl. Lung Cancer Res. 5, 455–465 (2016).
Levine, J.H. et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162, 184–197 (2015).
Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87, 636–645 (2015).
Weber, L.M. & Robinson, M. D. Comparison of clustering methods for high-dimensional single-cell flow and mass cytometry data. Cytometry A 89, 1084–1096 (2016).
Maaten, L.V.D. & Hinton, G. Visualizing data using tSNE. J. Mach. Learn. Res. 9, 2579–2605 (2008).
Nowicka, M. et al. CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. F1000Res. 6, 748 (2017).
Huang, A.C. et al. T cell invigoration to tumor burden ratio associated with anti-PD-1 response. Nature 545, 60–65 (2017).
Kamphorst, A.O. et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl. Acad. Sci. USA 114, 4993–4998 (2017).
Arvaniti, E. & Claassen, M. Sensitive detection of rare disease-associated cell subsets via representation learning. Nat. Commun. 8, 14825 (2017).
Brahmer, J.R. et al. Phase 1 study of single-agent anti-programmed-death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010).
Brahmer, J.R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).
Weber, J.S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375–384 (2015).
Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
Ribas, A. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. J. Am. Med. Assoc. 315, 1600–1609 (2016).
Ostrand-Rosenberg, S. & Sinha, P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182, 4499–4506 (2009).
Gebhardt, C. et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin. Cancer Res. 21, 5453–5459 (2015).
Meyer, C. et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63, 247–257 (2014).
Sade-Feldman, M. et al. Clinical significance of circulating CD33+CD11b+HLA-DR− myeloid cells in patients with stage IV melanoma treated with ipilimumab. Clin. Cancer Res. 22, 5661–5672 (2016).
Komohara, Y., Jinushi, M. & Takeya, M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 105, 1–8 (2014).
Zhang, Q.-W. et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 7, e50946 (2012).
Romano, E. et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc. Natl. Acad. Sci. USA 112, 6140–6145 (2015).
Chavan, R. et al. Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity. Cancer Immunol. Res. 2, 241–248 (2014).
Zaretsky, J.M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
Bellucci, R. et al. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. OncoImmunology 4, e1008824 (2015).
Daud, A.I. et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Invest. 126, 3447–3452 (2016).
Herbst, R.S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).
Kluger, H.M. et al. Characterization of PD-L1 expression and associated T cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin. Cancer Res. 21, 3052–3060 (2015).
von Andrian, U.H. & Mempel, T.R. Homing and cellular traffic in lymph nodes. Nat. Rev. Immunol. 3, 867–878 (2003).
Takizawa, H., Regoes, R.R., Boddupalli, C.S., Bonhoeffer, S. & Manz, M.G. Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation. J. Exp. Med. 208, 273–284 (2011).
Nagai, Y. et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 24, 801–812 (2006).
Caux, C., Moreau, I., Saeland, S. & Banchereau, J. Interferon-γ enhances factor-dependent myeloid proliferation of human CD34+ hematopoietic progenitor cells. Blood 79, 2628–2635 (1992).
Hartmann, F.J. et al. High-dimensional single-cell analysis reveals the immune signature of narcolepsy. J. Exp. Med. 213, 2621–2633 (2016).
Spidlen, J. & Brinkman, R.R. Use FlowRepository to share your clinical data upon study publication. Cytometry B Clin. Cytom. (2016).
Finck, R. et al. Normalization of mass cytometry data with bead standards. Cytometry A 83, 483–494 (2013).
Patro, R., Duggal, G., Love, M.I., Irizarry, R.A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417–419 (2017).
Soneson, C., Love, M.I. & Robinson, M.D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res. 4, 1521 (2015).
Robinson, M.D., McCarthy, D.J. & Smyth, G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
McCarthy, D.J., Chen, Y. & Smyth, G.K. Differential expression analysis of multifactor RNA-seq experiments with respect to biological variation. Nucleic Acids Res. 40, 4288–4297 (2012).